retatrutide phase 2 trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity New GLP-3 drug significantly slashes

( E H ) Average daily changes in body weight ( E )

Symptoms of a serious allergic reaction may include: swelling of your face, lips, tongue, or throat, fainting or feeling dizzy, very rapid heartbeat, problems breathing or swallowing, and severe rash or itching Talk with your health care provider if you are not sure if you are pregnant or planning to become pregnant

From short-acting to long-acting formulations, the wide range of GLP- 1 receptor agonists available provides physicians with numerous options to tailor treatment to each patient's needs

For most patients, shedding slows once weight stabilizes and resolves on its own within 3 to 6 months

The future of obesity care lies in embracing these advanced treatments

This comprehensive approach ensures that retatrutides benefits can be widely applied